Multi-modal characterization of metabolic and immune gene clusters in adrenocortical carcinoma treatment
Establishment of the TIME subtype According to recent literature, knowledge of the TIME should be the main emphasis…
Synthetic lethality in cancer drug discovery: challenges and opportunities
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…